
Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (OCE/CDER) Tamy Kim at tamy.kim@fda.hhs.gov or (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-8010.

**U.S. Department of Health and Human Services
Food and Drug Administration
Oncology Center of Excellence (OCE)
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
January 2025
Procedural**

Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway Guidance for Industry

Additional copies are available from:

*Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration*

*10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002*

Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353

Email: druginfo@fda.hhs.gov

*<https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>
and/or*

*Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration*

*10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002*

Phone: 800-835-4709 or 240-402-8010

Email: ocod@fda.hhs.gov

<https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>

**U.S. Department of Health and Human Services
Food and Drug Administration
Oncology Center of Excellence (OCE)
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
January 2025
Procedural**

Contains Nonbinding Recommendations

Draft — Not for Implementation

TABLE OF CONTENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

I. INTRODUCTION..... 2

II. BACKGROUND 3

**III. POLICY FOR REQUIRING A CONFIRMATORY TRIAL TO BE UNDERWAY
PRIOR TO APPROVAL..... 4**

A. *Confirmatory Trial Target Completion Date* 5

B. *Other Factors that FDA Intends to Consider When Deciding Whether a Trial is Underway*..... 6

C. *Anticipated Effect of Accelerated Approval on Participant Enrollment and Retention* 7

Contains Nonbinding Recommendations

Draft — Not for Implementation

35
36 **Accelerated Approval and Considerations for Determining**
37 **Whether a Confirmatory Trial is Underway**
38 **Guidance for Industry¹**
39

40
41 This draft guidance, when finalized, will represent the current thinking of the Food and Drug
42 Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not
43 binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the
44 applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible
45 for this guidance as listed on the title page.
46

47
48
49
50 **I. INTRODUCTION**

51
52 The accelerated approval provisions in section 506(c) of the Federal Food, Drug, and Cosmetic
53 Act (FD&C Act) provide that FDA may grant accelerated approval to:

54
55 [A] product for a serious or life-threatening disease or condition... upon a determination
56 product has an effect on a surrogate endpoint that is reasonably likely to predict
57 clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
58 ty or mortality, that is reasonably likely to predict an effect on irreversible
59 morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or
60 prevalence of the condition and the availability or lack of alternative treatments.²
61

62 For drugs³ granted accelerated approval, sponsors have been required to conduct confirmatory
63 studies postapproval to verify and describe the anticipated effect on irreversible morbidity or
64 mortality or other clinical benefit.⁴ In the Consolidated Appropriations Act, 2023, Congress
65 amended Section 506(c) of the FD&C Act to provide additional authorities to help ensure timely
66 completion of such trials, including that FDA “may require, as appropriate, a study or studies to

¹ This guidance has been prepared by the Oncology Center of Excellence (OCE), the Center for Drug Evaluation and Research (CDER), and the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.

² Section 506(c)(1)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

³ For the purposes of this guidance, all references to *drugs or drug products* include both human drugs and biological products regulated by CDER and CBER unless otherwise specified.

⁴ Section 506(c)(2)(A)(i) of the FD&C Act; see also 21 CFR 314.510 (“Approval under this section will be subject to the requirement that the applicant study the drug further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome.”).

Contains Nonbinding Recommendations

Draft — Not for Implementation

67 be underway prior to approval or within a specified time period after the date of approval, of the
68 applicable pr and produce furniture like tables and chairs dance describes FDA’s interpretation of the term “underway”, and
69 discusses policies for implementing this requirement, including factors FDA intends to consider
70 when determining whether a confirmatory trial^{6,7} is underway prior to accelerated approval.⁸

71
72 FDA’s guidance documents do not establish legally enforceable responsibilities. Instead,
73 guidances describe the Agency’s current thinking on a topic and should be viewed only as
74 recommendations, unless specific regulatory or statutory requirements are cited. The use of the
75 word *should* in Agency guidances means that something is suggested or recommended, but not
76 required.

77

78

79 II. BACKGROUND

80

81 At the time a drug product is granted accelerated approval, FDA has determined that an effect on
82 the endpoint used to support approval – a surrogate endpoint or an intermediate clinical endpoint
83 – is reasonably likely to predict clinical benefit. This allows earlier approval of products intended
84 to treat patients with serious and life-threatening conditions than under traditional approval,
85 where evidence of effectiveness is provided by trials that directly measure an effect on the
86 clinical outcome of interest, or on validated endpoints that have been extensively studied, and
87 commonly require more time to complete.

88

89 The risks of this approach include the possibility that patients may be exposed to the risks of a
90 drug that eventually fails to verify clinical benefit. In addition, a drug granted accelerated
91 approval is generally supported by smaller or shorter clinical trials than is typical for a drug

⁵ Section 506(c)(2)(D) of the FD&C Act; Pub. L. No. 117-328.

⁶ For purposes of section 506(c), FDA interprets the term “study” to include a clinical investigation such as a randomized, controlled trial, which is the type of confirmatory study that is typically required to confirm benefit, as well as other types of studies. In this guidance, references to a confirmatory “trial” or “study” should be understood to mean one or more trials or studies, as appropriate for the relevant product. The terms *trials* and *studies* are used interchangeably in this guidance. Policies regarding studies other than those that may be required under section 506(c) are beyond the scope of this guidance. Sponsors are encouraged to discuss with FDA early in the development process what studies should be conducted to verify and confirm benefit, and conditions for any such studies. The fact that this guidance refers to clinical trials as a type of clinical study should not be read to suggest that FDA considers clinical trials to be studies under section 505(o) of the FD&C Act, which authorizes FDA under specific conditions to require postapproval clinical trials and studies.

⁷ The terms *postapproval*, *postmarketing*, and *confirmatory* are used interchangeably throughout this guidance to describe the postapproval studies that FDA requires under section 506(c) of the FD&C Act. 21 CFR 314.510 refers to these postapproval studies as *postmarketing studies*, and the term *confirmatory studies* has commonly been used to describe studies that are completed postapproval and are intended to verify clinical benefit.

⁸ Other aspects of the accelerated approval program under section 506(c) of the FD&C Act and FDA regulations are beyond the scope of this guidance. For a fuller discussion of the accelerated approval authorities and FDA’s implementation of this program, see the draft guidance for industry *Expedited Programs for Serious Conditions – Accelerated Approval of Drugs and Biologics* (December 2024), available at <https://www.fda.gov/media/184120/download>. When final, this guidance will represent the FDA’s current thinking on this topic. Note that we update guidances periodically. For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

Contains Nonbinding Recommendations

Draft — Not for Implementation

92 receiving traditional approval, which may mean there is less information about the occurrence of
93 rare or delayed adverse events.

94

95 Sponsors have therefore been required to conduct postapproval trials to verify clinical benefit of
96 drugs granted accelerated approval. These confirmatory studies protect the public health and the
97 integrity of the drug approval process by balancing earlier approval of drugs with an assurance
98 that studies will be conducted to resolve residual uncertainty about benefit. Confirmatory trials
99 must be completed with due diligence.⁹ It is critical that such studies are promptly initiated and
100 completed in a timely manner to limit the time that a drug is approved for an indication without
101 verification of clinical benefit. This is especially important when the drug has considerable
102 toxicity because the longer the time between approval and verification of clinical benefit the
103 more patients will be exposed to the toxicity without verification of clinical benefit.

104

105 While many confirmatory trials are completed in a timely fashion, some have been slow to
106 initiate or have stalled, resulting in long delays or even uncertainty about whether studies can be
107 completed. In the Consolidated Appropriations Act, Congress provided FDA with additional
108 authorities to help prevent such delays, including that FDA may, when appropriate, require a
109 confirmatory study or studies to be underway prior to approval.⁹

110

111

112 **III. POLICY FOR REQUIRING A CONFIRMATORY TRIAL TO BE UNDERWAY** 113 **PRIOR TO APPROVAL**

114

115 Randomized controlled trials are commonly required to verify clinical benefit of a drug granted
116 accelerated approval and may be challenging to conduct (especially placebo-controlled studies)
117 if the trial is not underway when the drug is approved. For drug development programs intending
118 to seek accelerated approval, FDA generally intends to require that the confirmatory trial(s) be
119 underway prior to the accelerated approval action.¹⁰ If FDA determines that a confirmatory trial
120 must be underway prior to accelerated approval and the trial is not underway, FDA does not
121 intend to grant accelerated approval until this deficiency is addressed.¹¹ In some cases, when
122 FDA determines that continued enrollment/retention after the drug product is on the market is
123 likely to be especially challenging, FDA may require enrollment to be complete at the time of
124 approval.

125

126

⁹ FDA intends to address in other guidance complementary authorities added by the Consolidated Appropriations Act, 2023 to help ensure timely study completion. The Consolidated Appropriations Act authorizes FDA to specify the conditions for the progress of a required postapproval trial, which may include enrollment targets, the study protocol, and milestones, including the target date of study completion. See section 506(c)(2)(C) of the FD&C Act. Failure to conduct a trial with due diligence, including with respect to these conditions, can be grounds for withdrawing approval using expedited withdrawal procedures. See section 506(c)(3)(A). The Consolidated Appropriations Act also requires sponsors to submit reports to FDA on the progress of required confirmatory trials approximately every 180 days. See section 506B(a)(2).

¹⁰ Section 506(c)(2)(A), (C), (D).

¹¹ Section 506(c)(2)(D).

Contains Nonbinding Recommendations

Draft — Not for Implementation

127 There may be limited circumstances where FDA may not require the confirmatory trial to be
128 underway prior to accelerated approval. For example, the confirmatory trial may be dependent
129 on a future event, e.g., an infectious disease outbreak that has not yet occurred and at the time of
130 approval it would be infeasible to conduct a trial.

131
132 For certain rare diseases, the clinically relevant endpoints and disease natural history may enable
133 postmarketing studies that do not require randomization to verify clinical benefit, and this design
134 could reduce the challenge of enrolling and completing the study if it is not underway prior to
135 approval. FDA also recognizes that sponsors seeking approval for drugs intended to treat some
136 rare diseases, especially those with very small populations with high unmet need, may face
137 unique challenges with initiating postapproval confirmatory trials prior to approval. In these
138 circumstances, if appropriate justification is provided, FDA may not require that the
139 confirmatory trial is “underway” prior to accelerated approval.

140
141 We encourage sponsors to have early discussions with FDA on the plan and timeline for a
142 postapproval trial. This includes a proposed study design to verify benefit, timing for initiation of
143 the confirmatory study, and appropriate justification for the plan and timeline, so that plans can
144 be agreed upon prior to submission of an application.

145

146

IV. UNDERWAY DETERMINATION

148

149 Soon after sponsors and FDA reach preliminary alignment that a development program could
150 support accelerated approval, sponsors should request a meeting with FDA to discuss a
151 comprehensive drug development program, which includes plans for confirmatory trial(s), if
152 such plans are not already completed and agreed to. As soon as practicable, and generally soon
153 after the End-of-Phase 2 meeting, there should be agreement between FDA and the sponsor on
154 the design of the confirmatory trial(s) intended to verify and describe clinical benefit, including
155 FDA’s review of draft protocol(s). The trial must be feasible to conduct and appropriately
156 designed to verify and describe clinical benefit.

157

158 FDA generally intends to consider a confirmatory trial to be “underway” prior to accelerated
159 approval if (1) the trial has a target completion date that is consistent with diligent and timely
160 conduct of the trial, considering the nature of the trial’s design and objectives, (2) the sponsor’s
161 progress and plans for postapproval conduct of the trial provide sufficient assurance to expect
162 timely completion of the trial, and (3) enrollment of the confirmatory trial has been initiated.

163

16500 The discussion below provides more information about how target completion dates may be set
for the trial and factors that FDA intends to consider in deciding whether a trial is “underway”
prior to approval.

167

A. *Confirmatory Trial Target Completion Date*

168

169

170 The timelines for the confirmatory trial – and in particular, the expected completion date –
171 should be discussed with FDA prior to the submission of the application for accelerated
172 approval. The timeline for confirmatory trial completion should reflect timely completion of the

Contains Nonbinding Recommendations

Draft — Not for Implementation

173 trial, including diligent conduct of the trial by the sponsor in a manner that limits the amount of
174 time the drug will remain approved without verification of clinical benefit. Considerations to
175 inform the target trial completion date may include:

- 176
- 177 • Natural history of the disease (e.g., rate of disease progression)
- 178
- 179 • Availability of alternative treatments (e.g., impact of alternative treatments on study
180 participant recruitment before and after accelerated approval of the drug)
- 181
- 182 • Anticipated recruitment timeline (including consideration of potential challenges with
183 enrolling or retaining participants in the trial post-accelerated approval, see Section
184 IV.C.)
- 185
- 186 • Projected timeline for efficacy analysis(es), taking into consideration event rate(s)
187 and/or minimum follow-up required, depending on the outcome(s) of interest
- 188
- 189

190 Appropriate target completion dates may differ across therapeutic areas. In oncology, for
191 example, the median time from accelerated approval to verification of benefit is approximately 3
192 years (including FDA review) and has been decreasing over time.¹² Specific target completion
193 dates for a trial depend on more considerations than can be described here. In all cases, sponsors
194 should provide FDA with a clear and sound justification of the proposed target completion date
195 for the Agency’s consideration.

B. Other Factors that FDA Intends to Consider When Deciding Whether a Trial is Underway

199
200 FDA generally intends to consider a confirmatory trial to be “underway” for purposes of section
201 506(c)(2)(D) if the sponsor’s progress to date and plans for postapproval conduct of the trial
202 (specifically, the trial period intended to provide confirmation of benefit¹³) provide sufficient
203 assurance to expect timely completion of the trial. Considerations include:

- 204
- 205 • Accrual to date (including the rate of participant accrual), and projected rate of
206 participant accrual. If full enrollment is not expected prior to approval, the
207 sponsor should provide the anticipated timeline for complete enrollment after
208 accelerated approval.
- 209 • Number of active sites to date, projected rate of additional site activation

¹² See the November 16, 2023 Oncologic Drug Advisory Committee- FDA Briefing Document at <https://www.fda.gov/media/173780/download>.

¹³ In some cases, a trial design may include more than one phase, e.g., a dosing and run-in study may be conducted with a relatively small number of participants, with protocols that require the results of this phase to be evaluated before initiating the confirmatory phase of the trial (i.e., the phase that is designed to verify the clinical benefit of the drug). For purposes of section 506(c)(2)(D), FDA generally intends to consider enrollment in the confirmatory phase of the trial to be necessary to consider the confirmatory trial to be underway.

Contains Nonbinding Recommendations

Draft — Not for Implementation

(including U.S. and ex-U.S. locations)

210
211
212 The sponsor should propose benchmarks (including, e.g., participant recruitment goal, extent of
213 site activation, proportion of primary endpoint events accrued) consistent with the considerations
214 above that could be assessed at the time of the anticipated accelerated approval to facilitate
215 FDA's determination of whether the trial is underway. Benchmarks should be identified to allow
216 measurement of the sponsor's progress, which if met would provide assurance of the trial's
217 feasibility and allow the Agency to expect timely completion of the trial by an appropriate target
218 completion date. Sponsors should discuss with FDA whether the proposed benchmark(s) is/are
219 acceptable prior to submission of the application. Sponsors are expected to ensure adequate trial
220 resources such that implementation meets benchmark timelines.

221
222 If one or more sponsor benchmark(s) have not been met prior to the accelerated approval action
223 date, FDA intends to consider whether accelerated approval is appropriate after taking into
224 consideration the sponsor's justification for the delayed progress and the sponsor's plan to
225 address the delay.¹⁴

226
227 In many instances, including in rare disease development programs, a pre-planned assessment of
228 a surrogate or intermediate clinical endpoint from an ongoing trial may be able to support
229 accelerated approval, with the trial continuing after accelerated approval to verify clinical
230 benefit. Such a trial would be considered underway as long as the trial is expected to complete in
231 a timely manner.

232
233
234 ***C. Anticipated Effect of Accelerated Approval on Participant Enrollment and***
235 ***Retention***

236
237 In planning the timeline for a confirmatory trial, sponsors should consider factors that may
238 adversely affect accrual, including how an accelerated approval and wider availability of the
239 drug are expected to impact the accrual and conduct of the confirmatory trial. For example, the
240 impact of an accelerated approval may be limited if the confirmatory trial is not being conducted
241 in the approved indication (e.g., the confirmatory trial is to be conducted in an earlier disease
242 stage or different treatment setting). Alternatively, the impact of approval may be greater if the
243 confirmatory trial is in the same population as the approved indication, particularly if the trial is
244 not at full or near full enrollment at the time of accelerated approval. In the latter setting,
245 sponsors should mitigate the anticipated impact of accelerated approval on participant enrollment
246 and retention by completing all or a significant portion of enrollment prior to accelerated
247 approval. Additionally, to ensure the confirmatory trial enrolls and retains sufficient U.S.
248 participants, the sponsor's enrollment strategy should prioritize early U.S. recruitment, and U.S.
249 recruitment should be closer to completion at the time of accelerated approval.

¹⁴ Section 506(c)(2)(D).